Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Trial record 1 of 1 for:    COG ACNS02B3
Previous Study | Return to List | Next Study

Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2016 by Children's Oncology Group
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Children's Oncology Group
ClinicalTrials.gov Identifier:
NCT00919750
First received: June 11, 2009
Last updated: May 17, 2016
Last verified: May 2016
  Purpose
The purpose of this study is to collect and store brain tissue samples and blood from children with brain cancer that will be tested in the laboratory. Collecting and storing samples of tumor tissue and blood from patients to test in the laboratory may help the study of cancer in the future.

Condition Intervention
Childhood Atypical Teratoid/Rhabdoid Tumor
Childhood Central Nervous System Germ Cell Tumor
Childhood Choroid Plexus Tumor
Childhood Craniopharyngioma
Childhood Grade I Meningioma
Childhood Grade II Meningioma
Childhood Grade III Meningioma
Childhood High-grade Cerebral Astrocytoma
Childhood Infratentorial Ependymoma
Childhood Low-grade Cerebral Astrocytoma
Childhood Oligodendroglioma
Childhood Supratentorial Ependymoma
Newly Diagnosed Childhood Ependymoma
Recurrent Childhood Cerebellar Astrocytoma
Recurrent Childhood Cerebral Astrocytoma
Recurrent Childhood Ependymoma
Recurrent Childhood Medulloblastoma
Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
Recurrent Childhood Visual Pathway and Hypothalamic Glioma
Recurrent Childhood Visual Pathway Glioma
Other: cytology specimen collection procedure

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens

Resource links provided by NLM:


Further study details as provided by Children's Oncology Group:

Primary Outcome Measures:
  • Collection of brain tumor tissue and an accompanying blood sample from pediatric patients with brain tumors treated at Children's Oncology Group institutions [ Time Frame: Up to 16 years ] [ Designated as safety issue: No ]
  • Creation of a repository for long-term storage of these specimens [ Time Frame: Up to 16 years ] [ Designated as safety issue: No ]
  • Making these specimens available to qualified researchers to understand the biology of pediatric brain tumors [ Time Frame: Up to 16 years ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA
brain tumor tissue, blood

Estimated Enrollment: 5000
Study Start Date: March 2005
Estimated Primary Completion Date: January 2100 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Ancillary-Correlative (tissue and blood sample collection)
Brain tumor tissue and blood specimens are collected from patients and banked for future study. There are no sample size goals for this protocol and no projected closing date.
Other: cytology specimen collection procedure
Correlative studies
Other Name: cytologic sampling

Detailed Description:

OBJECTIVES:

I. Collect brain tumor tissue and an accompanying blood sample from pediatric patients with brain tumors treated at Children's Oncology Group institutions.

II. Provide a repository for long-term storage of specimens from these patients.

III. Make these specimens available to qualified researchers to understand the biology of pediatric brain tumors.

OUTLINE: This is a multicenter study.

Brain tumor tissue and blood specimens are collected from patients and banked for future study.

  Eligibility

Ages Eligible for Study:   up to 18 Years   (Child, Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All patients treated for a brain tumor at a COG institution are eligible for participation in this study.
Criteria

Inclusion Criteria:

  • Diagnosis of brain tumor
  • Previously treated at a Children's Oncology Group (COG) institution

    • Patients are eligible at time of diagnosis, second-look surgery, recurrence, or development of a second malignant neoplasm
  • Must have brain tumor biological specimens derived from primary tumors of the CNS available for submission
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00919750

  Show 182 Study Locations
Sponsors and Collaborators
Children's Oncology Group
National Cancer Institute (NCI)
Investigators
Principal Investigator: Scott Pomeroy Children's Oncology Group
  More Information

Responsible Party: Children's Oncology Group
ClinicalTrials.gov Identifier: NCT00919750     History of Changes
Obsolete Identifiers: NCT00228748
Other Study ID Numbers: ACNS02B3  NCI-2009-00334  COG-ACNS02B3  CDR0000352347  ACNS02B3  ACNS02B3  U10CA098543 
Study First Received: June 11, 2009
Last Updated: May 17, 2016
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Neoplasms
Glioma
Brain Neoplasms
Neoplasms, Germ Cell and Embryonal
Astrocytoma
Ependymoma
Oligodendroglioma
Meningioma
Neuroectodermal Tumors
Neuroectodermal Tumors, Primitive
Medulloblastoma
Craniopharyngioma
Adamantinoma
Rhabdoid Tumor
Choroid Plexus Neoplasms
Optic Nerve Glioma
Neoplasms, Neuroepithelial
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neoplasms, Vascular Tissue
Meningeal Neoplasms
Bone Neoplasms
Bone Diseases

ClinicalTrials.gov processed this record on September 27, 2016